41 related articles for article (PubMed ID: 29432734)
1. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.
Feng H; Yang Z; Bai X; Yang M; Fang Y; Zhang X; Guo Q; Ning H
Int J Mol Med; 2018 Apr; 41(4):2099-2107. PubMed ID: 29344639
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation.
Yang F; Sun S; Wang C; Haas M; Yeo S; Guan JL
Br J Cancer; 2020 Jun; 122(12):1791-1802. PubMed ID: 32336756
[TBL] [Abstract][Full Text] [Related]
4. mTORC1 accelerates osteosarcoma progression via m
Yang Z; Yu W; Xu A; Liu B; Jin L; Tao H; Wang D
Cell Death Discov; 2024 Mar; 10(1):127. PubMed ID: 38467635
[TBL] [Abstract][Full Text] [Related]
5. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.
Candido MF; Medeiros M; Veronez LC; Bastos D; Oliveira KL; Pezuk JA; Valera ET; Brassesco MS
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839989
[TBL] [Abstract][Full Text] [Related]
6. The roles of glycolysis in osteosarcoma.
Feng Z; Ou Y; Hao L
Front Pharmacol; 2022; 13():950886. PubMed ID: 36059961
[TBL] [Abstract][Full Text] [Related]
7.
Mohás A; Krencz I; Váradi Z; Arató G; Felkai L; Kiss DJ; Moldvai D; Sebestyén A; Csóka M
Pathol Oncol Res; 2022; 28():1610231. PubMed ID: 35392503
[TBL] [Abstract][Full Text] [Related]
8. Cold Atmospheric Plasma: A New Strategy Based Primarily on Oxidative Stress for Osteosarcoma Therapy.
Mateu-Sanz M; Tornín J; Ginebra MP; Canal C
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33672274
[TBL] [Abstract][Full Text] [Related]
9. The role of RICTOR amplification in targeted therapy and drug resistance.
Zhao D; Jiang M; Zhang X; Hou H
Mol Med; 2020 Feb; 26(1):20. PubMed ID: 32041519
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk.
Sheng J; Shen L; Sun L; Zhang X; Cui R; Wang L
Cell Prolif; 2019 May; 52(3):e12609. PubMed ID: 31033054
[TBL] [Abstract][Full Text] [Related]
11. HSP70 Acetylation Prevents Combined mTORC1/2 Inhibitor and Curcumin Treatment-Induced Apoptosis.
Seo SU; Min KJ; Woo SM; Seo JH; Kwon TK
Molecules; 2018 Oct; 23(11):. PubMed ID: 30356017
[TBL] [Abstract][Full Text] [Related]
12. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.
Zhu YR; Zhou XZ; Zhu LQ; Yao C; Fang JF; Zhou F; Deng XW; Zhang YQ
Oncotarget; 2016 Aug; 7(31):49527-49538. PubMed ID: 27385099
[TBL] [Abstract][Full Text] [Related]
13. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
14. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
15. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
16. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
